US 12,281,167 B2
Humanized anti-GDNF family alpha-receptor 4 (GRF-alpha-4) antibodies and chimeric antigen receptors (CARs)
Donald L. Siegel, Lansdale, PA (US); Vijay Bhoj, Philadelphia, PA (US); Christoph Rader, Jupiter, FL (US); and Rebecca Goydel, La Jolla, CA (US)
Assigned to The Trustees of the University of Pennsylvania, Philadelphia, PA (US); and University of Florida Research Foundation, Incorporated, Gainesville, FL (US)
Filed by The Trustees of the University of Pennsylvania, Philadelphia, PA (US); and University of FLorida Research Foundation, Incorporated, Gainesville, FL (US)
Filed on Sep. 27, 2023, as Appl. No. 18/475,958.
Application 18/475,958 is a continuation of application No. 17/037,203, filed on Sep. 29, 2020, granted, now 11,802,159.
Claims priority of provisional application 62/907,909, filed on Sep. 30, 2019.
Prior Publication US 2024/0067737 A1, Feb. 29, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01)
CPC C07K 16/2863 (2013.01) [A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/46432 (2023.05); A61K 39/464412 (2023.05); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70578 (2013.01); A61K 2039/505 (2013.01); A61K 2239/28 (2023.05); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); C07K 2317/24 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01)] 17 Claims
OG exemplary drawing
 
1. A modified immune cell or precursor cell thereof comprising a vector that comprises an isolated nucleic acid encoding a binding polypeptide that binds a glial cell derived neurotrophic factor (GDNF) family receptor alpha-4a (GFRα4a) or GFRα4b, wherein the isolated nucleic acid comprises a nucleotide sequence encoding:
(a) a heavy chain variable region comprising the nucleic acid sequence of SEQ ID NO: 2 and a light chain variable region comprising the nucleic acid sequence of SEQ ID NO: 13, 15, 18, 22, or 23;
(b) a heavy chain variable region comprising the nucleic acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the nucleic acid sequence of SEQ ID NO: 13 or 22;
(c) a heavy chain variable region comprising the nucleic acid sequence of SEQ ID NO: 4 and a light chain variable region comprising the nucleic acid sequence of SEQ ID NO: 13, 15, 18, or 22; or
(d) a heavy chain variable region comprising the nucleic acid sequence of SEQ ID NO: 5 and a light chain variable region comprising the nucleic acid sequence of SEQ ID NO: 13 or 18.